Core Insights - Marvel Biosciences Corp. has selected Novotech as the contract research organization for its upcoming Phase I clinical trial of the lead drug candidate MB-204, which targets autism spectrum disorder and related conditions [1][2] - The partnership with Novotech is expected to enhance the efficiency of the Phase I program due to Australia's favorable regulatory environment and significant tax credits [2] Company Overview - Marvel Biosciences Corp. is a Calgary-based biotechnology company focused on developing new treatments for neurological diseases and neurodevelopmental disorders, with its lead drug candidate MB-204 being a novel adenosine A2A antagonist [3] - MB-204 is a fluorinated derivative of Istradefylline, an approved Parkinson's drug, and is being explored for its potential in treating conditions such as autism, depression, and rare disorders like Rett syndrome and Fragile X syndrome [3]

For personal use only Investor presentation 27 August 2025 IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES P aa g e� 1 1 Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties . Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to be correct . Actual results could differ materially from those anticip ...